NASDAQ:CMMB   Chemomab Therapeutics Ltd.
I've mentioned Chemomab Therapeutics Ltd (NASDAQ:CMMB) for the bulls out there. On Friday, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $42 per share. It seems that analysts are also seeing what I'm seeing, a stock trading at bargain prices with a tremendous potential going forward and a very low float. From a technical standpoint, the stock has built a good support around $19.2 and $20 recently and does have the chance to go up. Any breakout above the $25 level next week would be a positive sign.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.